1. Pdcd4 delays and attenuates papilloma development in a dose-dependent manner.
Pdcd4 delays and attenuates papilloma development in a dose-dependent manner. Pdcd4-C1, Pdcd4-G6, and wild-type siblings (7-8 weeks old) were initiated topically with DMBA (100 nmol). Mice were treated topically twice weekly with TPA (5 nmol per treatment) for 26 weeks. A, papilloma multiplicity (measured through 25 weeks) was reduced with Pdcd4-C1 and Pdcd4-G6 transgenic mice by 45% and 65%, respectively. B, papilloma incidence (percentage mice bearing papilloma) was delayed by 4 weeks in both Pdcd4-C1 and Pdcd4-G6 transgenic mice. All acetone mice were negative for papilloma development and not plotted. C, as mice were terminated from the experiment due to carcinoma invasion, uninvolved epidermis and papillomas were randomly chosen from wild-type and Pdcd4-G6 mice. Western blot analysis of extracts was done with anti-Pdcd4 antibody. An invariant nonspecific band was used for loading control comparisons.
Aaron P. Jansen et al. Cancer Res 2005;65:
©2005 by American Association for Cancer Research